Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis
Background. The association between lipoprotein-associated phospholipase A2 (Lp-PLA2) and stroke risk is inconsistent. We conducted a meta-analysis to determine whether elevated Lp-PLA2 is a risk factor for stroke. Methods. Studies were included if they reported Lp-PLA2 mass and/or activity levels a...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2019-01, Vol.2019 (2019), p.1-11 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | 2019 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2019 |
| creator | Hu, Yunzhao Huang, Weijun Tong, Huiyu Liu, Deping Hu, Gaifeng Huang, Yuli |
| description | Background. The association between lipoprotein-associated phospholipase A2 (Lp-PLA2) and stroke risk is inconsistent. We conducted a meta-analysis to determine whether elevated Lp-PLA2 is a risk factor for stroke. Methods. Studies were included if they reported Lp-PLA2 mass and/or activity levels and adjusted risk estimates of stroke. The primary outcome was overall stroke incidence. The combined results were shown as relative risks (RRs) with 95% confidence intervals (CI) for per 1 standard deviation (SD) higher value of Lp-PLA2 and the highest versus lowest Lp-PLA2 category. Results. Twenty-two studies involving 157,693 participants were included for analysis. After adjusting for conventional risk factors, the RRs for overall stroke with 1 SD higher Lp-PLA2 activity and mass were 1.07 (95% CI 1.02–1.13) and 1.11 (95% CI 1.04–1.19), respectively. The RRs of ischemic stroke with 1 SD higher Lp-PLA2 activity and mass were 1.08 (95% CI 1.01–1.15) and 1.11 (95% CI 1.02–1.22), respectively. When comparing the highest and lowest levels of Lp-PLA2, the RRs of stroke for Lp-PLA2 activity and mass were 1.26 (95% CI 1.03–1.54) and 1.56 (95% CI 1.21–2.00), respectively. Finally, when comparing the highest and lowest levels of Lp-PLA2, the pooled RRs of ischemic stroke for Lp-PLA2 activity and mass were 1.29 (95% CI 1.07–1.56) and 1.68 (95% CI 1.12–2.53), respectively. Conclusions. Elevated baseline Lp-PLA2 levels, detected either by activity or mass, are associated with increased stroke risk. |
| doi_str_mv | 10.1155/2019/8642784 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6545803</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A612030612</galeid><sourcerecordid>A612030612</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-28a68f704601ec1a0b70d53891bcbb1c7e4c7e5004e60d9d608c3befbbeb07b3</originalsourceid><addsrcrecordid>eNqNkV1rFDEUhgdRbKm981oC3gg69uRjMjNeCEOxWtiiaO9DkjnTTTs7mSbZyv57s-y6Va8M5APy8OScvEXxksJ7SqvqjAFtzxopWN2IJ8Ux41SUkgr69HDm_Kg4jfEW8miohFY-L444ZVwKKo4Lv3Czn4NP6Kayi9FbpxP25NvSx3npRzfriKRjpLPJPbi0IXrqyZWOkehILqceZ8zLlMh3F-_IhbbJB-IH8iMFf4cfSEeuMOmym_S4iS6-KJ4Neox4ut9PiuuLT9fnX8rF18-X592itKJtU8kaLZuhBiGBoqUaTA19xZuWGmsMtTWKPCsAgRL6tpfQWG5wMAYN1IafFB932nltVtjbXGDQo5qDW-mwUV479ffN5Jbqxj8oWYmqAZ4Fb_aC4O_XGJNauWhxHPWEfh0VY0K2UOX_z-jrf9Bbvw653y3FeU2zrnqkbvSIyk2Dz-_arVR1kjLgkNdMvdtRNvgYAw6HkimobeJqm7jaJ57xV3-2eYB_55uBtztg6aZe_3T_qcPM4KAfacoaEJT_AjkTvAc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2233710335</pqid></control><display><type>article</type><title>Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Hu, Yunzhao ; Huang, Weijun ; Tong, Huiyu ; Liu, Deping ; Hu, Gaifeng ; Huang, Yuli</creator><contributor>Demarin, Vida</contributor><creatorcontrib>Hu, Yunzhao ; Huang, Weijun ; Tong, Huiyu ; Liu, Deping ; Hu, Gaifeng ; Huang, Yuli ; Demarin, Vida</creatorcontrib><description>Background. The association between lipoprotein-associated phospholipase A2 (Lp-PLA2) and stroke risk is inconsistent. We conducted a meta-analysis to determine whether elevated Lp-PLA2 is a risk factor for stroke. Methods. Studies were included if they reported Lp-PLA2 mass and/or activity levels and adjusted risk estimates of stroke. The primary outcome was overall stroke incidence. The combined results were shown as relative risks (RRs) with 95% confidence intervals (CI) for per 1 standard deviation (SD) higher value of Lp-PLA2 and the highest versus lowest Lp-PLA2 category. Results. Twenty-two studies involving 157,693 participants were included for analysis. After adjusting for conventional risk factors, the RRs for overall stroke with 1 SD higher Lp-PLA2 activity and mass were 1.07 (95% CI 1.02–1.13) and 1.11 (95% CI 1.04–1.19), respectively. The RRs of ischemic stroke with 1 SD higher Lp-PLA2 activity and mass were 1.08 (95% CI 1.01–1.15) and 1.11 (95% CI 1.02–1.22), respectively. When comparing the highest and lowest levels of Lp-PLA2, the RRs of stroke for Lp-PLA2 activity and mass were 1.26 (95% CI 1.03–1.54) and 1.56 (95% CI 1.21–2.00), respectively. Finally, when comparing the highest and lowest levels of Lp-PLA2, the pooled RRs of ischemic stroke for Lp-PLA2 activity and mass were 1.29 (95% CI 1.07–1.56) and 1.68 (95% CI 1.12–2.53), respectively. Conclusions. Elevated baseline Lp-PLA2 levels, detected either by activity or mass, are associated with increased stroke risk.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2019/8642784</identifier><identifier>PMID: 31236414</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>1-Alkyl-2-acetylglycerophosphocholine Esterase - blood ; 1-Alkyl-2-acetylglycerophosphocholine Esterase - genetics ; Aged ; Arteriosclerosis ; Atherosclerosis ; Biomarkers - blood ; Cardiovascular disease ; Cohort Studies ; Confidence intervals ; FDA approval ; Female ; Health risk assessment ; Health risks ; Heart ; Humans ; Internal medicine ; Ischemia ; Lipoproteins ; Male ; Medical research ; Medicine, Experimental ; Meta-analysis ; Metabolism ; Metabolites ; Middle Aged ; Mortality ; Phospholipase ; Phospholipase A2 ; Phospholipases ; Prospective Studies ; Quality ; Risk analysis ; Risk Factors ; Stroke ; Stroke (Disease) ; Stroke - blood ; Stroke - epidemiology ; Stroke - genetics ; Stroke - pathology ; Studies ; Thrombosis</subject><ispartof>BioMed research international, 2019-01, Vol.2019 (2019), p.1-11</ispartof><rights>Copyright © 2019 Gaifeng Hu et al.</rights><rights>COPYRIGHT 2019 John Wiley & Sons, Inc.</rights><rights>Copyright © 2019 Gaifeng Hu et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2019 Gaifeng Hu et al. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-28a68f704601ec1a0b70d53891bcbb1c7e4c7e5004e60d9d608c3befbbeb07b3</citedby><cites>FETCH-LOGICAL-c499t-28a68f704601ec1a0b70d53891bcbb1c7e4c7e5004e60d9d608c3befbbeb07b3</cites><orcidid>0000-0001-5104-567X ; 0000-0003-2299-3560</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545803/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545803/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31236414$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Demarin, Vida</contributor><creatorcontrib>Hu, Yunzhao</creatorcontrib><creatorcontrib>Huang, Weijun</creatorcontrib><creatorcontrib>Tong, Huiyu</creatorcontrib><creatorcontrib>Liu, Deping</creatorcontrib><creatorcontrib>Hu, Gaifeng</creatorcontrib><creatorcontrib>Huang, Yuli</creatorcontrib><title>Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Background. The association between lipoprotein-associated phospholipase A2 (Lp-PLA2) and stroke risk is inconsistent. We conducted a meta-analysis to determine whether elevated Lp-PLA2 is a risk factor for stroke. Methods. Studies were included if they reported Lp-PLA2 mass and/or activity levels and adjusted risk estimates of stroke. The primary outcome was overall stroke incidence. The combined results were shown as relative risks (RRs) with 95% confidence intervals (CI) for per 1 standard deviation (SD) higher value of Lp-PLA2 and the highest versus lowest Lp-PLA2 category. Results. Twenty-two studies involving 157,693 participants were included for analysis. After adjusting for conventional risk factors, the RRs for overall stroke with 1 SD higher Lp-PLA2 activity and mass were 1.07 (95% CI 1.02–1.13) and 1.11 (95% CI 1.04–1.19), respectively. The RRs of ischemic stroke with 1 SD higher Lp-PLA2 activity and mass were 1.08 (95% CI 1.01–1.15) and 1.11 (95% CI 1.02–1.22), respectively. When comparing the highest and lowest levels of Lp-PLA2, the RRs of stroke for Lp-PLA2 activity and mass were 1.26 (95% CI 1.03–1.54) and 1.56 (95% CI 1.21–2.00), respectively. Finally, when comparing the highest and lowest levels of Lp-PLA2, the pooled RRs of ischemic stroke for Lp-PLA2 activity and mass were 1.29 (95% CI 1.07–1.56) and 1.68 (95% CI 1.12–2.53), respectively. Conclusions. Elevated baseline Lp-PLA2 levels, detected either by activity or mass, are associated with increased stroke risk.</description><subject>1-Alkyl-2-acetylglycerophosphocholine Esterase - blood</subject><subject>1-Alkyl-2-acetylglycerophosphocholine Esterase - genetics</subject><subject>Aged</subject><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Biomarkers - blood</subject><subject>Cardiovascular disease</subject><subject>Cohort Studies</subject><subject>Confidence intervals</subject><subject>FDA approval</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Health risks</subject><subject>Heart</subject><subject>Humans</subject><subject>Internal medicine</subject><subject>Ischemia</subject><subject>Lipoproteins</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Meta-analysis</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Phospholipase</subject><subject>Phospholipase A2</subject><subject>Phospholipases</subject><subject>Prospective Studies</subject><subject>Quality</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Stroke</subject><subject>Stroke (Disease)</subject><subject>Stroke - blood</subject><subject>Stroke - epidemiology</subject><subject>Stroke - genetics</subject><subject>Stroke - pathology</subject><subject>Studies</subject><subject>Thrombosis</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkV1rFDEUhgdRbKm981oC3gg69uRjMjNeCEOxWtiiaO9DkjnTTTs7mSbZyv57s-y6Va8M5APy8OScvEXxksJ7SqvqjAFtzxopWN2IJ8Ux41SUkgr69HDm_Kg4jfEW8miohFY-L444ZVwKKo4Lv3Czn4NP6Kayi9FbpxP25NvSx3npRzfriKRjpLPJPbi0IXrqyZWOkehILqceZ8zLlMh3F-_IhbbJB-IH8iMFf4cfSEeuMOmym_S4iS6-KJ4Neox4ut9PiuuLT9fnX8rF18-X592itKJtU8kaLZuhBiGBoqUaTA19xZuWGmsMtTWKPCsAgRL6tpfQWG5wMAYN1IafFB932nltVtjbXGDQo5qDW-mwUV479ffN5Jbqxj8oWYmqAZ4Fb_aC4O_XGJNauWhxHPWEfh0VY0K2UOX_z-jrf9Bbvw653y3FeU2zrnqkbvSIyk2Dz-_arVR1kjLgkNdMvdtRNvgYAw6HkimobeJqm7jaJ57xV3-2eYB_55uBtztg6aZe_3T_qcPM4KAfacoaEJT_AjkTvAc</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Hu, Yunzhao</creator><creator>Huang, Weijun</creator><creator>Tong, Huiyu</creator><creator>Liu, Deping</creator><creator>Hu, Gaifeng</creator><creator>Huang, Yuli</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5104-567X</orcidid><orcidid>https://orcid.org/0000-0003-2299-3560</orcidid></search><sort><creationdate>20190101</creationdate><title>Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis</title><author>Hu, Yunzhao ; Huang, Weijun ; Tong, Huiyu ; Liu, Deping ; Hu, Gaifeng ; Huang, Yuli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-28a68f704601ec1a0b70d53891bcbb1c7e4c7e5004e60d9d608c3befbbeb07b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>1-Alkyl-2-acetylglycerophosphocholine Esterase - blood</topic><topic>1-Alkyl-2-acetylglycerophosphocholine Esterase - genetics</topic><topic>Aged</topic><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Biomarkers - blood</topic><topic>Cardiovascular disease</topic><topic>Cohort Studies</topic><topic>Confidence intervals</topic><topic>FDA approval</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Health risks</topic><topic>Heart</topic><topic>Humans</topic><topic>Internal medicine</topic><topic>Ischemia</topic><topic>Lipoproteins</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Meta-analysis</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Phospholipase</topic><topic>Phospholipase A2</topic><topic>Phospholipases</topic><topic>Prospective Studies</topic><topic>Quality</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Stroke</topic><topic>Stroke (Disease)</topic><topic>Stroke - blood</topic><topic>Stroke - epidemiology</topic><topic>Stroke - genetics</topic><topic>Stroke - pathology</topic><topic>Studies</topic><topic>Thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Yunzhao</creatorcontrib><creatorcontrib>Huang, Weijun</creatorcontrib><creatorcontrib>Tong, Huiyu</creatorcontrib><creatorcontrib>Liu, Deping</creatorcontrib><creatorcontrib>Hu, Gaifeng</creatorcontrib><creatorcontrib>Huang, Yuli</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Yunzhao</au><au>Huang, Weijun</au><au>Tong, Huiyu</au><au>Liu, Deping</au><au>Hu, Gaifeng</au><au>Huang, Yuli</au><au>Demarin, Vida</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>2019</volume><issue>2019</issue><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Background. The association between lipoprotein-associated phospholipase A2 (Lp-PLA2) and stroke risk is inconsistent. We conducted a meta-analysis to determine whether elevated Lp-PLA2 is a risk factor for stroke. Methods. Studies were included if they reported Lp-PLA2 mass and/or activity levels and adjusted risk estimates of stroke. The primary outcome was overall stroke incidence. The combined results were shown as relative risks (RRs) with 95% confidence intervals (CI) for per 1 standard deviation (SD) higher value of Lp-PLA2 and the highest versus lowest Lp-PLA2 category. Results. Twenty-two studies involving 157,693 participants were included for analysis. After adjusting for conventional risk factors, the RRs for overall stroke with 1 SD higher Lp-PLA2 activity and mass were 1.07 (95% CI 1.02–1.13) and 1.11 (95% CI 1.04–1.19), respectively. The RRs of ischemic stroke with 1 SD higher Lp-PLA2 activity and mass were 1.08 (95% CI 1.01–1.15) and 1.11 (95% CI 1.02–1.22), respectively. When comparing the highest and lowest levels of Lp-PLA2, the RRs of stroke for Lp-PLA2 activity and mass were 1.26 (95% CI 1.03–1.54) and 1.56 (95% CI 1.21–2.00), respectively. Finally, when comparing the highest and lowest levels of Lp-PLA2, the pooled RRs of ischemic stroke for Lp-PLA2 activity and mass were 1.29 (95% CI 1.07–1.56) and 1.68 (95% CI 1.12–2.53), respectively. Conclusions. Elevated baseline Lp-PLA2 levels, detected either by activity or mass, are associated with increased stroke risk.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>31236414</pmid><doi>10.1155/2019/8642784</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-5104-567X</orcidid><orcidid>https://orcid.org/0000-0003-2299-3560</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2019-01, Vol.2019 (2019), p.1-11 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6545803 |
| source | MEDLINE; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | 1-Alkyl-2-acetylglycerophosphocholine Esterase - blood 1-Alkyl-2-acetylglycerophosphocholine Esterase - genetics Aged Arteriosclerosis Atherosclerosis Biomarkers - blood Cardiovascular disease Cohort Studies Confidence intervals FDA approval Female Health risk assessment Health risks Heart Humans Internal medicine Ischemia Lipoproteins Male Medical research Medicine, Experimental Meta-analysis Metabolism Metabolites Middle Aged Mortality Phospholipase Phospholipase A2 Phospholipases Prospective Studies Quality Risk analysis Risk Factors Stroke Stroke (Disease) Stroke - blood Stroke - epidemiology Stroke - genetics Stroke - pathology Studies Thrombosis |
| title | Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T06%3A38%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipoprotein-Associated%20Phospholipase%20A2%20Activity%20and%20Mass%20as%20Independent%20Risk%20Factor%20of%20Stroke:%20A%20Meta-Analysis&rft.jtitle=BioMed%20research%20international&rft.au=Hu,%20Yunzhao&rft.date=2019-01-01&rft.volume=2019&rft.issue=2019&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2019/8642784&rft_dat=%3Cgale_pubme%3EA612030612%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2233710335&rft_id=info:pmid/31236414&rft_galeid=A612030612&rfr_iscdi=true |